Keefe, Bruyette & Woods dropped their price target on shares of KB Home from $85.00 to $76.00 and set a “market perform” rating on the stock in a research note on Friday, January 17th.

Stocks rose in volatile trading on Wednesday morning, led by the Energy and Communication Services sectors. Biogen shares jumped 38% after the company reported positive data from an Alzheimer's ...

In addition, we provide compelling evidence for the utility of the NF-κB subunit, Rel A, as a prognostic marker and as a therapeutic target in this disease, and we also describe how this protein ...

TOKYO -- Researchers from Japan's Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

"We had to develop new methods to detect and quantify not just off-target editing but also the wide variety of gene edits at the intended target site. Many people are unaware of the complexities ...

KB Securities analyzed that L&F reported earnings for the fourth quarter of 2024 that fell short of market forecasts. Consequently, they maintained a 'buy' rating, but downgraded the target price ...

Treatment with TNFα and high glucose levels that mimic the inflammatory response in diabetic patients not only resulted in the loss of the repressive histone modifications H3K9me3 and H3K27me3, ...

If, as Martone et al. (2) estimated, there are ~10 4 consensus κB sites in the genome that are bound by RelA and ~1 × 10 5 RelA-containing dimers enter the nucleus upon cell stimulation [estimated by ...

sgRNAs were designed to target multiple loci in the human genome with computational ... mCherry vector (modified from Addgene no. 46914), replacing the mCherry marker gene with BFP to monitor sgRNA ...

Certain members of the IκB protein family have now been shown to selectively up-regulate the transcription of specific NF-κB target genes by providing transactivating activity to the otherwise ...